Form 4: Marinus Pharmaceuticals Director Noonberg Receives Stock Options and Restricted Stock Units

Director Sarah B. Noonberg acquired stock options and restricted stock units in Marinus Pharmaceuticals on June 18, 2024.

Summary

• On June 18, 2024, Sarah B. Noonberg, a director of Marinus Pharmaceuticals, acquired 2,300 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest in full on July 15, 2025, contingent upon Noonberg's continued service with the company.
• Each RSU represents the right to receive one share of Marinus Pharmaceuticals common stock.
• Noonberg also acquired options to purchase 10,450 shares of common stock at an exercise price of $1.40 per share.
• These options vest and become fully exercisable on July 15, 2025, also subject to continued service with the Issuer.
• Following these transactions, Noonberg directly owns 10,450 derivative securities and 14,100 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs to a director is a common practice and generally viewed as a positive sign of aligning management's interests with shareholders. There are no explicitly negative aspects in the filing.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule tied to continued service incentivizes the director to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of RSUs and stock options is contingent upon continued service with the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates changes in Noonberg's beneficial ownership of Marinus Pharmaceuticals' securities.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs as a positive sign, aligning the director's interests with the company's long-term success.
• The director is incentivized to remain with the company and contribute to its growth.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Sarah B. Noonberg, Director, Stock Options, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4